Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...

CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...

For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.

CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epilepsy. Detailed revenue breakdown from Q3 2024 10-Q highlights FIRDAPSE as the main revenue driver.

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...

Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst ...

(RTTNews) - Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company, Tuesday announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE or amifampridine ...

"We are pleased that our sub-licensee, DyDo, has launched FIRDAPSE in Japan. We believe in health equity, and this launch is a testament to our ongoing efforts to increase patient access to life ...

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva ...